Skip to content

Attitudes of Pregnant Women and Healthcare Professionals Toward Clinical Trials and Routine Implementation of Antenatal Vaccination Against Respiratory Syncytial Virus: A Multicenter Questionnaire Study

Research output: Contribution to journalArticle

  • Christopher R. Wilcox
  • Anna Calvert
  • Jane Metz
  • Eliz Kilich
  • Rachael MacLeod
  • Kirsten Beadon
  • Paul T. Heath
  • Asma Khalil
  • Adam Finn
  • Matthew D. Snape
  • Tushna Vandrevala
  • Tom Nadarzynski
  • Matthew A. Coleman
  • Christine E. Jones
Original languageEnglish
Pages (from-to)944-951
Number of pages8
JournalPediatric Infectious Disease Journal
Issue number9
DateAccepted/In press - 23 Apr 2019
DatePublished (current) - 1 Sep 2019


Respiratory Syncytial Virus (RSV) is a common cause of infant hospitalisation and mortality. With multiple vaccines in development, we aimed to determine
[1] the awareness of RSV amongst pregnant women and healthcare professionals (HCPs), and
[2] attitudes towards clinical trials and routine implementation of antenatal RSV vaccination.

Separate questionnaires for pregnant women and HCPs were distributed within four hospitals in South England (July 2017-January 2018).

Responses from 314 pregnant women and 204 HCPs (18% obstetricians, 75% 82 midwives, 7% unknown) were analyzed. Most pregnant women (88%) and midwives (66%) had no/very little awareness of RSV, unlike obstetricians (14%). Amongst pregnant women, 29% and 75% would likely accept RSV vaccination as part of a trial, or if routinely-recommended, respectively. Younger women (16-24 years), those of 21-30 weeks’ gestation, and with experience of RSV were significantly more likely to participate in trials (OR: 1.42 [1.72-9.86]; OR: 2.29 [1.22-4.31]; OR: 9.07 [1.62-50.86], respectively). White-British women and those of 21-30 weeks’ gestation were more likely to accept routinely recommended vaccination (OR: 2.16 [1.07-4.13]; OR: 2.10 [1.07-4.13]). Obstetricians were more likely than midwives to support clinical trials (92% vs. 68%, OR: 2.50, 1.01-6.16) and routine RSV vaccination (89% vs. 79%, OR: 4.08, 1.53-9.81), as were those with prior knowledge of RSV, and who deemed it serious.

RSV awareness is low amongst pregnant women and midwives. Education will be required to support successful implementation of routine antenatal 4 vaccination. Research is needed to understand reasons for vaccine hesitancy amongst pregnant women and HCPs, particularly midwives.

    Research areas

  • Vaccination, pregnancy, RESPIRATORY SYNCYTIAL VIRUS, RSV, clinical trials, Attitudes



  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Lippincott, Williams & Wilkins at . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 492 KB, PDF document

    Embargo ends: 1/09/20

    Request copy


View research connections

Related faculties, schools or groups